Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety, Tolerability, and Pharmacokinetics of Multiple Doses of TBN in Healthy Subjects
NCT04667013Phase 1Not yet recruiting
- Sponsor
- Guangzhou Magpie Pharmaceutical
- Start
- Sep 2028
- Primary completion
- Mar 2029
- Modality
- Classical Binding Small Molecules
01
Overview
Phase 1, randomised, double-blind trial of tetramethylpyrazine nitrone in ischemic stroke (2 cohorts), sponsored by Guangzhou Magpie Pharmaceutical. Primary endpoints: Adverse Events at 14 days, Assessment of physical examination at 14 days and 4 more. Planned start Sep 2028; status: not yet recruiting.
02
Drugs
tetramethylpyrazine nitrone
03
Conditions
ischemic stroke
Beyond the preview
Go deeper on NCT04667013.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04667013.